Navigation Links
Peregrine Pharmaceuticals Receives Approval to Begin New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer
Date:11/16/2007

- Republic of Georgia Drug Agency Approves Protocol for New Clinical Trial

of Bavituximab in Combination with Docetaxel -

TUSTIN, Calif., Nov. 16 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a clinical stage biopharmaceutical company developing monoclonal antibodies for the treatment of cancer and hepatitis C virus (HCV) infection, today announced that its Phase II clinical protocol to study bavituximab in combination with the chemotherapy drug docetaxel in patients with metastatic breast cancer has been approved by the Drug Agency of the Ministry of Labour, Health and Social Affairs of Georgia. The open label, multi-center safety and efficacy trial is expected to begin enrolling patients by early 2008.

The primary objective of the trial is to assess the overall response rate to the combination of bavituximab with docetaxel, a chemotherapy drug commonly used in the treatment of metastatic breast cancer. Secondary objectives include measuring time to tumor progression, duration of response, overall patient survival and safety parameters. In the trial's two-stage design, up to 15 patients with metastatic breast cancer will be enrolled initially. The study will then be expanded up to a total of 46 patients if promising results are observed. The trial is expected to enroll patients at a minimum of three clinical trial sites.

"We are eager to assess bavituximab's potential in Phase II combination studies in a number of cancer indications, and we are very pleased to have received prompt regulatory approval to proceed with this breast cancer trial," said Steven W. King, president and CEO of Peregrine. "The clinical sites in the Republic of Georgia that will be par
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Positive Results From Peregrine Pharmaceuticals Bavituximab Phase l HCV Trial Presented at AASLD Meeting
2. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
3. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
4. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
5. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
6. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
7. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
8. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
9. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
10. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
11. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/3/2015)... EMBARGOED FOR RELEASE UNTIL 2 P.M. ET, WEDNESDAY, ... of Mother’s Home to Gas Wells , PITTSBURGH, June 3, ... of natural gas wells drilled with hydraulic fracturing were more ... living farther from such wells, according to a University ... southwestern Pennsylvania birth records. , The finding does not ...
(Date:6/3/2015)... York, NY (PRWEB) June 03, 2015 ... agreed to pay $7.8 million to resolve a Risperdal ... Arkansas over tactics the company allegedly used to market ... County Circuit Court indicate that the Arkansas Attorney General ... part of the accord. The Risperdal settlement amounts to ...
(Date:6/3/2015)... 2015 Follow us on LinkedIn ... revolutionized disease treatment on account of their better mode ... such as rheumatoid arthritis. The industry is expected to ... small molecule drugs to biopharmaceuticals over the coming years. ... and gene therapies, and recombinant proteins has attracted industry ...
(Date:6/3/2015)... (PRWEB) June 03, 2015 Dr. Steven Reisman, ... Cardiac Diagnostic Center ( http://www.newyorkcardiac.com ) located in NYC, announced ... weekdays to his practice. In most cases, depending on the ... the day they call, they will be seen by a ... priority as a cardiologist is to ensure that people who ...
(Date:6/3/2015)... York, NY (PRWEB) June 03, 2015 ... strategic partnership to expand online and mobile access ... Board Review and Maintenance of Certification (MOC) activities. ... will market VeoMed’s innovative courses to Decker’s extensive ... professionals interested in purchasing access to VeoMed’s premier ...
Breaking Medicine News(10 mins):Health News:Fracking Proximity Associated with Lower Birth Weight 2Health News:Fracking Proximity Associated with Lower Birth Weight 3Health News:Fracking Proximity Associated with Lower Birth Weight 4Health News:Risperdal Lawsuit News: Johnson & Johnson, Janssen Settle Arkansas Marketing Case for $7.8 Million 2Health News:Risperdal Lawsuit News: Johnson & Johnson, Janssen Settle Arkansas Marketing Case for $7.8 Million 3Health News:Risperdal Lawsuit News: Johnson & Johnson, Janssen Settle Arkansas Marketing Case for $7.8 Million 4Health News:Superior Efficacy of Biopharmaceuticals Against Chronic Diseases Drives the Global Biopharmaceuticals Market, According to a New Report by Global Industry Analysts, Inc. 2Health News:Superior Efficacy of Biopharmaceuticals Against Chronic Diseases Drives the Global Biopharmaceuticals Market, According to a New Report by Global Industry Analysts, Inc. 3Health News:Superior Efficacy of Biopharmaceuticals Against Chronic Diseases Drives the Global Biopharmaceuticals Market, According to a New Report by Global Industry Analysts, Inc. 4Health News:NYC Cardiologist, Dr. Steven Reisman, Announces Same Day and Evening Appointments 2Health News:VeoMed and Decker Intellectual Properties, the Owner of Scientific American Medicine, Announce a Partnership to Expand Access to Premier Online CME Courses 2
... The Sanitizer, Game Allows Consumers to Zap Germs in the Water Just ... ... 20 Just in time for Memorial Day,integrated marketing communications agency, Fletcher ... BioGuard,s new UV sanitizing unit, BioLab UV ( http://www.biolabuv.com ). ...
... is a well known disease entity that has a wide ... the colonic blood supply is key to its development. However, ... causes ischemia of the bowel. This report describes the first ... and splenic veins. , This case report, from a ...
... not uncommon to find tissue that normally lines the stomach ... tissue has been identified in such diverse locations as the ... case, reported by a team led by Dr. Steven Paul ... the World Journal of Gastroenterology. , Typically, when this gastric ...
... no obvious effects on MKN-45 cells proliferation and apoptosis. At ... apoptosis improved. It may be that CO2 gas affected the ... by a team led by Professor Pei-Wu Yu. The research ... World Journal of Gastroenterology. , There is an ongoing debate ...
... and calm, according to a new study from the Population ... at about age 60, participants reported more feelings of ease ... John Mirowsky, professors of sociology, have published the findings in ... issue of Social Science and Medicine. The research was funded ...
... substantial financial income and the ... chance to change people,s lives, ... so,people are increasingly looking for new ways to make the ... Today, that,s,possible with the independent marketing opportunities provided by,Melaleuca, The ...
Cached Medicine News:Health News:Fletcher Martin Creates Interactive Game-Ad for BioLab(R) UV for BioGuard(R) 2Health News:Heterotopic gastric tissue simulating acute appendicitis 2Health News:With age comes a sense of peace and calm 2Health News:Lucrative Sales Opportunities Abound With Melaleuca, The Wellness Company(R) 2
(Date:6/3/2015)... , June 3, 2015  Lightlake Therapeutics ... addiction treatments based on its expertise in opioid ... Lightlake,s partner for treating opioid overdose with intranasal ... New Drug Application (NDA) to the United States ... spray formulation of naloxone, a drug intended to ...
(Date:6/3/2015)... 3, 2015  Halozyme Therapeutics, Inc. (NASDAQ: ... license agreement with AbbVie (NYSE: ABBV ) to ... with Halozyme,s ENHANZE ™ platform. ... will receive an initial $23 million payment, followed ... each of up to nine collaboration targets. These ...
(Date:6/3/2015)... 2015  VA North Texas Health Care System ... vBloc, a technology-based, scientifically advanced weight loss therapy.  ... called the Maestro® Rechargeable System that intermittently blocks ... involving food intake and processing between the brain ... customizable to meet the needs of a patient,s ...
Breaking Medicine Technology:Lightlake Therapeutics Inc. Announces Adapt Pharma Limited Commences Rolling NDA Submission To The FDA For Intranasal Naloxone 2Lightlake Therapeutics Inc. Announces Adapt Pharma Limited Commences Rolling NDA Submission To The FDA For Intranasal Naloxone 3Halozyme Enters Into Global Collaboration and Licensing Agreement With AbbVie 2Halozyme Enters Into Global Collaboration and Licensing Agreement With AbbVie 3VA North Texas First VA in the Country to Perform vBloc Implant, a Cutting-Edge Weight Loss Therapy 2VA North Texas First VA in the Country to Perform vBloc Implant, a Cutting-Edge Weight Loss Therapy 3
Worn by many professional athletes, EpiTrain is our most popular elbow support....
EpiPoint is a dynamic elbow strap for tennis elbow and other overuse conditions....
... Mayo Clinic Elbow Brace, featuring an innovative ... stability and comfort while allowing for immobilization, ... the elbow. The sturdy metal uprights provide ... hold the brace in position, ensure patient ...
... AliMed® Turnbuckle Elbow Orthosis applies ... extension or flexion. Controls elbow contracture ... unbalanced muscle strength. Also good for ... turnbuckle is tightened to apply tension ...
Medicine Products: